Dewpoint Therapeutics announced a development candidate in its MYC program — a first‑in‑class small molecule designed to modulate aberrant biomolecular condensates that organize oncogenic transcription. The candidate aims to disrupt MYC‑driven transcriptional programs by altering condensate properties rather than inhibiting enzymatic activity. The nomination reflects a growing industry interest in targeting phase separation and condensate biology as a way to access previously undruggable transcription factors. Dewpoint said preclinical data support target engagement and downstream transcriptional modulation. If translational and safety hurdles are met, condensate modulators could open new routes to treat MYC‑addicted cancers that resist conventional approaches.